...
abcl-img

Abcellera Biologics Inc, Common Stock

ABCL

NSQ

$2.825

+$0.04

(1.43%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$844.75M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
1.68M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.35
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$2.33 L
$6.05 H
$2.825

About Abcellera Biologics Inc, Common Stock

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameABCLSectorS&P500
1-Week Return-7.62%-3.39%0.2%
1-Month Return5.28%-1.92%2.72%
3-Month Return2.2%-10.54%7.31%
6-Month Return-8.82%-4.47%10.44%
1-Year Return-47.56%4.06%27.53%
3-Year Return-81.38%0.94%30.88%
5-Year Return-95.26%36.67%89.21%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue11.61M233.16M11.61M485.42M38.02M[{"date":"2019-12-31","value":2.39,"profit":true},{"date":"2020-12-31","value":48.03,"profit":true},{"date":"2021-12-31","value":2.39,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":7.83,"profit":true}]
Cost of Revenue10.11M27.14M45.52M66.44M30.89M[{"date":"2019-12-31","value":15.22,"profit":true},{"date":"2020-12-31","value":40.86,"profit":true},{"date":"2021-12-31","value":68.51,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":46.5,"profit":true}]
Gross Profit1.50M206.01M11.61M418.99M38.02M[{"date":"2019-12-31","value":0.36,"profit":true},{"date":"2020-12-31","value":49.17,"profit":true},{"date":"2021-12-31","value":2.77,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":9.08,"profit":true}]
Gross Margin12.91%88.36%100.00%86.31%100.00%[{"date":"2019-12-31","value":12.91,"profit":true},{"date":"2020-12-31","value":88.36,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":86.31,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Expenses13.95M41.66M13.95M191.92M275.23M[{"date":"2019-12-31","value":5.07,"profit":true},{"date":"2020-12-31","value":15.14,"profit":true},{"date":"2021-12-31","value":5.07,"profit":true},{"date":"2022-12-31","value":69.73,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income(4.12M)156.03M(4.12M)216.51M(237.21M)[{"date":"2019-12-31","value":-1.9,"profit":false},{"date":"2020-12-31","value":72.07,"profit":true},{"date":"2021-12-31","value":-1.9,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-109.56,"profit":false}]
Total Non-Operating Income/Expense1.85M(4.42M)11.31K34.62M105.42M[{"date":"2019-12-31","value":1.76,"profit":true},{"date":"2020-12-31","value":-4.19,"profit":false},{"date":"2021-12-31","value":0.01,"profit":true},{"date":"2022-12-31","value":32.84,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Pre-Tax Income(2.21M)157.83M(2.21M)239.10M(174.03M)[{"date":"2019-12-31","value":-0.92,"profit":false},{"date":"2020-12-31","value":66.01,"profit":true},{"date":"2021-12-31","value":-0.92,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-72.79,"profit":false}]
Income Taxes209.20K38.91M65.69M80.58M(27.63M)[{"date":"2019-12-31","value":0.26,"profit":true},{"date":"2020-12-31","value":48.29,"profit":true},{"date":"2021-12-31","value":81.52,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-34.29,"profit":false}]
Income After Taxes(2.42M)118.92M(67.90M)158.52M(146.40M)[{"date":"2019-12-31","value":-1.53,"profit":false},{"date":"2020-12-31","value":75.02,"profit":true},{"date":"2021-12-31","value":-42.83,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-92.35,"profit":false}]
Income From Continuous Operations(2.21M)118.92M153.46M158.52M(146.40M)[{"date":"2019-12-31","value":-1.39,"profit":false},{"date":"2020-12-31","value":75.02,"profit":true},{"date":"2021-12-31","value":96.81,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-92.35,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(2.42M)118.92M(2.21M)158.52M(146.40M)[{"date":"2019-12-31","value":-1.53,"profit":false},{"date":"2020-12-31","value":75.02,"profit":true},{"date":"2021-12-31","value":-1.39,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-92.35,"profit":false}]
EPS (Diluted)(0.00)0.400.470.50(0.52)[{"date":"2019-12-31","value":-0.48,"profit":false},{"date":"2020-12-31","value":79.36,"profit":true},{"date":"2021-12-31","value":94,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-104,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

ABCL
Cash Ratio 8.08
Current Ratio 9.34

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

ABCL
ROA (LTM) -13.26%
ROE (LTM) -15.55%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

ABCL
Debt Ratio Lower is generally better. Negative is bad. 0.23
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.77

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

ABCL
Trailing PE NM
Forward PE 27.47
P/S (TTM) 25.63
P/B 0.78
Price/FCF NM
EV/R 8.28
EV/Ebitda 5.30

FAQs

What is Abcellera Biologics Inc share price today?

Abcellera Biologics Inc (ABCL) share price today is $2.825

Can Indians buy Abcellera Biologics Inc shares?

Yes, Indians can buy shares of Abcellera Biologics Inc (ABCL) on Vested. To buy Abcellera Biologics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ABCL stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Abcellera Biologics Inc be purchased?

Yes, you can purchase fractional shares of Abcellera Biologics Inc (ABCL) via the Vested app. You can start investing in Abcellera Biologics Inc (ABCL) with a minimum investment of $1.

How to invest in Abcellera Biologics Inc shares from India?

You can invest in shares of Abcellera Biologics Inc (ABCL) via Vested in three simple steps:

  • Click on Sign Up or Invest in ABCL stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Abcellera Biologics Inc shares
What is Abcellera Biologics Inc 52-week high and low stock price?

The 52-week high price of Abcellera Biologics Inc (ABCL) is $6.05. The 52-week low price of Abcellera Biologics Inc (ABCL) is $2.33.

What is Abcellera Biologics Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Abcellera Biologics Inc (ABCL) is

What is Abcellera Biologics Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Abcellera Biologics Inc (ABCL) is 0.78

What is Abcellera Biologics Inc dividend yield?

The dividend yield of Abcellera Biologics Inc (ABCL) is 0.00%

What is the Market Cap of Abcellera Biologics Inc?

The market capitalization of Abcellera Biologics Inc (ABCL) is $844.75M

What is Abcellera Biologics Inc’s stock symbol?

The stock symbol (or ticker) of Abcellera Biologics Inc is ABCL

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top